Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 known ✓ | P23219 | 2/20 | 0.61 |
| ▸ | EGFR known ✓ | P00533 | 1/20 | 0.61 |
| ▸ | LCK known ✓ | P06239 | 1/20 | 0.61 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.61 |
| ▸ | PTGS2 known ✓ | P35354 | 1/20 | 0.61 |
| ▸ | TTR known ✓ | P02766 | 1/20 | 0.48 |
| ▸ | SLC7A5 | Q01650 | 5/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | USP2 | O75604 | 1/20 | 0.61 |
| ▸ | FYN | P06241 | 1/20 | 0.61 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.61 |
| ▸ | RECQL | P46063 | 1/20 | 0.61 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.48 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.48 |
| ▸ | KDM6B | O15054 | 1/20 | 0.48 |
| ▸ | HRAS | P01112 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4188588 | 1.00 | SLC7A5 (0.61) | SLC7A5PTGS1KDM4EUSP2EGFR | |
| SCHEMBL1070495 | 0.99 | SLC7A5 (0.63) | SLC7A5PTGS1KDM4EUSP2EGFR | |
| SCHEMBL31453291 | 0.99 | SLC7A5 (0.63) | SLC7A5PTGS1KDM4EUSP2EGFR | |
| SCHEMBL11440820 | 0.99 | SLC7A5 (0.63) | SLC7A5PTGS1KDM4EUSP2EGFR | |
| SCHEMBL10694411 | 0.88 | SLC7A5 (0.57) | SLC7A5PTGS1KDM4EUSP2EGFR | |
| SCHEMBL19115126 | 0.88 | SLC7A5 (0.57) | SLC7A5PTGS1KDM4EUSP2EGFR | |
| SCHEMBL28391235 | 0.88 | SLC7A5 (0.57) | SLC7A5PTGS1KDM4EUSP2EGFR | |
| Hydrochloric Acid SCHEMBL29098553 | 0.87 | LTA4H (0.48) | SLC7A5PTGS1KDM4EUSP2EGFR | |
| SCHEMBL14617681 | 0.86 | SLC7A5 (0.48) | SLC7A5PTGS1KDM4EUSP2EGFR | |
| SCHEMBL27406548 | 0.86 | SLC7A5 (0.50) | SLC7A5PTGS1KDM4EUSP2EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4241082-A | 3,4-DIHYDROXYPHENYLALANINE OR DERIVATIVE THEREOF AS A DECARBOXYLASE INHIBITOR USED IN CONJUNCTION WITH AN AMINO ACID | SANKYO COMPANY LIMITED (JP) | 1980-12-23 | — | — | US | claimed |
| CN-116964069-A | Stabilized liquid compositions comprising levodopa-tyrosine conjugates and uses thereof | 纽罗德姆有限公司 | 2023-10-27 | — | — | CN | disclosed |
| US-20090170937-A1 | Amino Acid Derivatives | PROXIMAGEN LTD. (GB) | 2009-07-02 | — | — | US | disclosed |
| US-20090036525-A1 | Non-Natural Amino Acid Derivatives | POXIMAGEN LTD. (GB) | 2009-02-05 | — | — | US | disclosed |
| EP-1981901-A1 | AMINO ACID DERIVATIVES | Proximagen Ltd. (GB) | 2008-10-22 | — | — | EP | disclosed |
| EP-1981839-A1 | NON-NATURAL AMINO ACID DERIVATIVES | Proximagen Ltd. (GB) | 2008-10-22 | — | — | EP | disclosed |
| WO-2007091018-A1 | NON-NATURAL AMINO ACID DERIVATIVES | PROXIMAGEN LTD. (GB) | 2007-08-16 | — | — | WO | disclosed |
| WO-2007091017-A1 | AMINO ACID DERIVATIVES | PROXIMAGEN LTD. (GB) | 2007-08-16 | — | — | WO | disclosed |
| US-4241082-A | 3,4-DIHYDROXYPHENYLALANINE OR DERIVATIVE THEREOF AS A DECARBOXYLASE INHIBITOR USED IN CONJUNCTION WITH AN AMINO ACID | SANKYO COMPANY LIMITED (JP) | 1980-12-23 | — | — | US | disclosed |
| US-4065566-A | PRO-DRUG FORM OF L-DOPA, PARKINSON*S DISEASE | INTERX RESEARCH CORPORATION (US) | 1977-12-27 | — | — | US | disclosed |
| US-4035507-A | Novel, transient pro-drug forms of L-DOPA to treat Parkinson's disease | INTERX RESEARCH CORPORATION (US) | 1977-07-12 | — | — | US | disclosed |
| US-3998799-A | FOR TREATMENT OF PARKINSON'S DISEASE | INTERX RESEARCH CORPORATION (US) | 1976-12-21 | — | — | US | disclosed |
| US-3939253-A | Novel, transient pro-drug forms of l-dopa useful in the treatment of parkinson's disease | INTERX RESEARCH CORPORATION (US) | 1976-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036525-A1 | Non-Natural Amino Acid Derivatives | CHRNA6, PARK7, CHRNA7 | PTGS1 2993/4885EGFR 817/4885LCK 3375/4885 |
| US-20090170937-A1 | Amino Acid Derivatives | PARK7, PRMT7, ADCY7 | PTGS1 3273/4885EGFR 433/4885LCK 2992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.